article thumbnail

Building a better future for people with rare diseases in all four UK nations

pharmaphorum

Published in January, the document replaces 2013’s UK Strategy for Rare Diseases and sets out four priorities for the next five years: faster diagnosis, increasing awareness among healthcare professionals, the better coordination of care, and improving access to specialist care, treatments, and drugs.

article thumbnail

Under FDORA, FDA to Require Most Drug and Device Trials to Submit Diversity Action Plans

The FDA Law Blog

Livornese — Last month, Congress took a big step towards improving clinical trial diversity by requiring sponsors of most drug and device clinical studies to submit a diversity action plan when they submit key trial documents to the Food and Drug Administration (FDA).

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma 4.0™ Is Gaining Momentum and Driving Innovation

ISPE

™ started in 2015 at the ISPE Germany/Austria/Switzerland (D/A/CH) “Plug and Produce” workshop in Basel, Switzerland. Is the vendors’ documentation complete in order to assess GxP risks and GxP compliance? Christian Wölbeling, Körber Pharma, Germany, gave an overview addressing where we are with Pharma 4.0.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. Published May 2006. 33 HealthXL. Published September 2021.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. Published May 2006. 33 HealthXL. Published September 2021.